RxDoctor Payments Data

Kaitlin King

Family · Phoenix, AZNPI 1801325162

Payments from drug & device makers

$3,985in general payments, 2019–2025

Across 190 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$866
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$541
  • Novo Nordisk$400
  • Pfizer$164
  • Takeda Pharmaceuticals U.S.A., Inc.$132
  • plus $807 from 22 others

What the payments were for

  • Food & beverage$3,972100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,985 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$46,679
Medicare patients
173
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$54,719
FarxigaDapagliflozin Propanediol24$29,305
MounjaroTirzepatide23$23,368
EliquisApixaban11$14,196
Xigduo XrDapaglifloz Propaned/Metformin12$10,443
SynthroidLevothyroxine Sodium29$2,342
Gabapentin91$1,935
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,885
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,357
Levothyroxine Sodium130$1,329
Rosuvastatin Calcium103$1,217
Tamsulosin Hcl35$1,123
Liothyronine Sodium23$1,053
Atorvastatin Calcium124$1,007
ValacyclovirValacyclovir Hcl18$975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$400$54,71937 claims
AstraZenecaFarxiga$866$29,30524 claims
Lilly USA, LLCMounjaro$53$23,36823 claims
PfizerEliquis$164$14,19611 claims
AbbVieSynthroid$1,076$2,34229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →